Skip to main content Skip to search Skip to main navigation

DRA Pakistan: Rapid Alert on Falsified Propylene Glycol

The Drug Regulatory Authority of Pakistan (DRAP) issued a Rapid Alert on 22 August 2024 regarding counterfeit batches of Propylene Glycol. The batches are tagged with Dow Chemical labels, and some are declared to be from 'Dow Europe GmbH, Made in Germany'.

DRAP received the information from Dow Chemical's subsidiary in Singapore and the responsible  WHO's safety unit. The warning refers to three batches, two allegedly from Dow Europe GmbH (Made in Germany) and one from The Dow Chemical Company. The labels are counterfeit and the quality and safety of the material cannot be guaranteed, according to DRAP. DRAP therefore calls on companies not to use these batches to manufacture medicines.

Companies that have used these batches should have their retained samples analysed immediately. If the samples are contaminated, the affected products should be recalled. In addition, raw materials should be screened before use and finished products should be specifically tested for contamination. More detailed information on the affected batches, including photos of the falsified containers, can be found here.

Meanwhile, the contaminated raw materials have been secured, and an investigation has been initiated. This announcement is the latest in a series of warnings from DRAP regarding propylene glycol in Pakistan.


Source:

Drug Regulatory Authority of Pakistan, Recall Alerts

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

PIC/S: Jordan FDA Joins PIC/S

PIC/S: Jordan FDA Joins PIC/S

On 1 January 2026, the Jordan Food & Drug Administration (JFDA) became the 57th PIC/S Participating Authority.

Read more
Swissmedic: Scientific GMDP Meetings

Swissmedic: Scientific GMDP Meetings

Swissmedic offers companies holding or seeking a Swissmedic manufacturing or distribution license the opportunity to discuss project-specific GMP and GDP topics in Scientific GMDP Meetings.

Read more
Purified Water – The new Chinese Pharmacopoeias and What Happens Next? NEU

Purified Water – The new Chinese Pharmacopoeias and What Happens Next? NEU

A new Chinese Pharmacopoeia was published in 2025. This has some significant implications for the pharmaceutical water industry, which we will discuss in more detail in this article. Firstly, it is important to note that cold WFI systems are now permitted worldwide and can be used across the board.
Read more
What are the requirements for gas distribution systems?

What are the requirements for gas distribution systems?

You can view the answer here:
Read more
What are the quality requirements for pharmaceutical gases?

What are the quality requirements for pharmaceutical gases?

You can view the answer here:
Read more
EMA: Update on the Guideline “Stability Testing for Variations”

EMA: Update on the Guideline “Stability Testing for Variations”

The EMA has updated the guideline on stability testing for variations (Revision 3, applicable from 15 January 2026).
Read more
Previous
Next